Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Documentation of high blood pressure measurements in the emergency department: factors associated with discussion and comparison to other settings.

Internal and emergency medicine·2026
Same author

Association of documented high blood pressure measurements with time to hypertension diagnosis.

The American journal of medicine·2025
Same author

Factors Associated With Discussing High Blood Pressure Readings in Clinical Notes.

American journal of hypertension·2024
Same author

A cluster randomized trial to evaluate a centralized remote clinical pharmacy service in large, health system primary care clinics.

Journal of the American College of Clinical Pharmacy : JACCP·2023
Same author

Characterization of Potassium-Induced Natriuresis in Hypertensive Postmenopausal Women During Both Low and High Sodium Intake.

Hypertension (Dallas, Tex. : 1979)·2022
Same author

Effect of a Physician/Pharmacist Collaborative Care Model on Time in Target Range for Systolic Blood Pressure: Post Hoc Analysis of the CAPTION Trial.

Hypertension (Dallas, Tex. : 1979)·2021
Same journal

Editor's page.

Journal of the American Society of Hypertension : JASH·2018
Same journal

BRD4 expression in patients with essential hypertension and its effect on blood pressure in spontaneously hypertensive rats.

Journal of the American Society of Hypertension : JASH·2018
Same journal

The variance of hypertension prevalence detected by epidemiological survey against clinical practice: data from a rural population in South China.

Journal of the American Society of Hypertension : JASH·2018
Same journal

Systolic and diastolic blood pressure percentiles by age and gender in Northeastern Iran.

Journal of the American Society of Hypertension : JASH·2018
Same journal

Editorial commentary on AHA scientific statement on meditation and cardiovascular risk reduction.

Journal of the American Society of Hypertension : JASH·2018
Same journal

Neck circumference and blood pressure among children: a systematic review and meta-analysis.

Journal of the American Society of Hypertension : JASH·2018
See all related articles

Related Experiment Videos

Combination therapy in hypertension.

Alan H Gradman1, Jan N Basile, Barry L Carter

  • 1The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania and Temple University School of Medicine, Philadelphia, PA, USA. gradmanmd@aol.com

Journal of the American Society of Hypertension : JASH
|April 20, 2010
PubMed
Summary
This summary is machine-generated.

Achieving blood pressure (BP) targets often requires combination therapy for hypertension. This position paper explores the scientific basis, drug choices, and patient selection for effective combination antihypertensive strategies.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Management

Background:

  • Antihypertensive therapy aims to reduce cardiovascular (CV) risks from elevated blood pressure (BP) without compromising quality of life.
  • BP reduction is the primary driver of CV risk reduction, with at least 75% of patients needing combination therapy to reach BP goals.

Purpose of the Study:

  • To present a position paper on combination therapy for hypertension from the American Society of Hypertension.
  • To address the scientific basis and pharmacologic rationale for specific antihypertensive drug combinations.
  • To review patient selection criteria and discuss fixed-dose combinations and recent trial implications.

Main Methods:

  • Review of scientific literature on combination antihypertensive therapy.
  • Analysis of pharmacologic principles for selecting drug combinations.
  • Evaluation of clinical trial data on specific combination strategies.

Main Results:

  • BP reduction per se is the key determinant of CV risk reduction.
  • Combination therapy is frequently required to achieve target BP levels in hypertensive patients.
  • Fixed-dose combination pills offer practical advantages for consistent BP control.

Conclusions:

  • Combination therapy is essential for effective hypertension management in a majority of patients.
  • Strategic selection of drug combinations and patient criteria optimizes BP control and CV risk reduction.
  • Further research and clinical practice emphasis are needed for consistent achievement and maintenance of goal BP.